A Special Message from Dean Wilkes

The July 4 holiday begins the most popular time for summer vacations for many of us. I wish for each of you a well-deserved rest. Prior to vacation season, I’d like to share some good news about our School.

Even though we’ve not reached the June 30 end of the current fiscal year, it’s clear that you have knocked it out of park in all areas of our School’s mission.

In education

  • The incoming class of 156 medical students has a mean GPA of 3.86 and a mean MCAT of 518.27 (the 97th percentile!). This year the class is 57% out-of-state and continues to have good diversity. The BIMS PhD programs have recruited a strong new class of graduate students.
  • 99% of our class matched in outstanding post-graduate programs.
  • Richard Baylis, MD/PhD student in the lab of Gary Owens, attended the 68th Lindau Nobel Laureate Meeting in June, where he and other young investigators from around the world had the opportunity to mingle with and get feedback from 43 Nobel Laureates.
  • All of the accrediting bodies that were required to approve the establishment of the School of Medicine-Inova Campus did so without stipulation. Our admissions team is getting ready to start recruiting the class of 2023, which will be the first class to have the option to do their clerkships at the Inova Campus.

In the clinical realm

  • Over 25% of our physicians are included on the 2017-18 Best Doctors in America list. This is phenomenal!
  • Becker’s Hospital Review recognized our hospital as one of the 100 Great Hospitals in America in 2018.
  • Our hospital continues to be #1 in Virginia.

And in research

  • SOM funding is poised to exceed last year’s totals, thanks to the continued outstanding efforts of all of our faculty and new strategic hires.
  • We scored a 21 on our CTSA application! Although we’ll know more in August, a number of people outside of UVA have confirmed that this is an extraordinary score.
  • The Hartwell Foundation again named UVA as one of its Top Ten Centers of Biomedical Research.
  • The UVA IRBs received accreditation from the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP).
  • The U.S. News & World Report rankings were further evidence of the extraordinary work you do. Primary Care rose to 21 (from 24) and Research went to 26 (from 27).

Finally, the School is in a strong financial position with operating revenues exceeding expenditures. Year-to-date through May 2018, the School of Medicine had an operating net income of $8 million. The Dean’s Reserve funded $31 million in strategic investments in all mission areas in clinical and basic science departments, as well as in centers. In addition, with strong financial management at all levels, we are entering our fourth consecutive year of no tuition increase for medical students.

You, our faculty, are the reason we have had such a remarkable year and are in a strong position both academically and fiscally. I am deeply grateful to you for your commitment to our shared vision and for your hard work that has resulted in this banner year for our School.

With warm regards,

David S. Wilkes, MD
Dean, UVA School of Medicine
James Carroll Flippin Professor of Medical Science

Research Integrity Matters

Dean David Wilkes

The “I” in our University of Virginia Health System ASPIRE value system, which stands for “integrity,” has been on my mind as of late. A few years ago, while at Indiana University School of Medicine, my colleagues and I published an article in Science Translation Medicine (STM), on which I was the senior investigator. I later hired a fellow to reproduce the data in my lab. He was unsuccessful. Simply stated, he was unable to match the success illustrated in the article.

I looked into why this was happening. We discovered that another post-doctorate fellow, the first author on the STM article, had manipulated data. I requested that the institution’s research compliance committee conduct an investigation into possible research fraud. During this investigation, it was discovered that handwritten data did not match the data on the hard drive of an oximeter. This confirmed our suspicion that this post-doctorate fellow had manipulated the data. Because of this incident, the STM article in question will be retracted later this year.

The point: integrity matters.

Science requires open and clean data. This is one of the reasons why our collaboration with AstraZeneca has been so successful — in the lab, our teams work side-by-side with their teams. Additionally, because data requires integrity, I’ve asked Peggy Shupnik, PhD, Senior Associate Dean for Research, to explore how we can help our faculty ensure that what happened to me does not happen to you. As part of an ongoing discussion, we will be exploring options to increase openness, integrity, and reproducibility of research.

Please learn from my experience. As a biomedical enterprise, it is incumbent upon all of us to closely monitor the data we generate. Discovery is not discovery if the data is fiction. I ask all of you to be aware of what is happening in our labs.

While all of the letters in our ASPIRE acronym are important, none of them are worthwhile without the “I” of integrity.

David S. Wilkes, MD
Dean, UVA School of Medicine
James Carroll Flippin Professor of Medical Science

Highlights: June MAC Meeting

The School of Medicine’s Medical Advisory Committee (MAC) met on June 12, 2018, 4-5 p.m., in the Biomedical Sciences classroom. Here are highlights from that meeting:

Closed Session
The meeting began with a closed session restricted to department chairs and the dean’scabinet.

Research Integrity
David S. Wilkes, MD
Dean Wilkes discussed the importance of open, clean data that can be reproduced and the importance of monitoring the quality of work that trainees and others are doing in the lab. He underscored these points by sharing his experience about a paper of his, published in Science Translational Medicine, that will be retracted in the next few months.

Dean Wilkes described how a new fellow in his lab at Indiana University was unsuccessful in reproducing data. Dean Wilkes began a probe and discovered that a post-doctorate fellow had manipulated data. Dean Wilkes asked the institution’s research integrity committee to conduct an investigation into possible research fraud. The results confirmed his suspicion and led to the upcoming retraction.

Further stressing the need for open and clean data, Dean Wilkes said one reason the AstraZeneca collaboration is successful is because the AZ investigators are in the lab, side-by-side with our investigators. Everyone is aware of what is happening. He shared that Dr. Shupnik will explore a partnership with the Center for Open Science, based here at UVA.

The next meeting will be on Tuesday, July 10, 2018, in the BIMS Classroom.

Highlights: May MAC Meeting

The School of Medicine’s Medical Advisory Committee (MAC) met on May 8, 2018, 4-5 p.m., in the Biomedical Sciences classroom. Here are highlights from that meeting:

StandPoint Survey
Susan Pollart, MD, Senior Associate Dean for Faculty Affairs and Faculty Development

  • In 2015, the SOM had an outstanding 74% response rate to the AAMC Faculty Forward survey. (The survey is now known as StandPoint.) The survey indicated a number of things the faculty wanted from the Dean’s office:
    • more transparency regarding SOM finances;
    • more communication from the dean’s office about the medical school;
    • more opportunity for participation in SOM governance; and
    • improvement in retaining high quality faculty members.
  • Actions were taken at the dean’s office in follow up to these data.
    • In the areas of communication and governance, Dean Wilkes engaged the SOM faculty senators in regular governance discussions, a department annual review programs was implemented, the Junior Faculty Development Program was launched, and new channels of communication were established (e.g., Dean’s Office Blog, social media, senior leadership attendance at department faculty meetings.).
    • Among the actions in the area of diversity, equity, and inclusion were the appointments of diversity facilitators and development of diversity plans in every department, sharing of best practices, and system-wide unconscious bias training.
    • To help bring transparency to SOM finances, the Financial Advisory Committee was created, the dean and CMO discussed finances in department faculty meetings, and departments received monthly consolidated financial reports.

3 Cavaliers Program
Melur Ramasubramanian, PhD, Vice President for Research

Ram gave an overview of the “3 Cavs,” a pilot program to stimulate new ideas and cross-discipline and cross-school collaborations. It is designed to minimize bureaucracy and maximize flexibility.

  • Research trios are formed by three faculty members who wish to collaborate on a new idea. The trio must cross at least two disparate disciplines located in different units or schools. A faculty expertise database will help researchers find collaborators.
  • Each member of the trio receives a “token” for $20,000, which provides the trio with a total of $60,000 in seed funds. At least 50% of each project must support a trainee who works with the researcher. The remaining funds may be used for non-salary items to support the project. The funds may not be used to pay faculty salaries. Mini-trios, with $5,000 tokens (total of $15,000) are also possible.
  • Projects are for one year. They are semi-randomly selected without peer review, and funding is provided immediately.
  • SOM full-time tenured and tenure-eligible faculty will be eligible to receive a token. The SOM funds one-third of the expense for each token and the VPR funds two-thirds.
  • The VPR’s office is still building the website with an anticipated go-live date in early July and a submission deadline in September. The SOM will send additional details at go-live.
  • Additional information, a brochure, and FAQs are on the VPR website.

2018 General Assembly Session
Federal Legislative and Regulatory Issues
Carol Craig, Government Relations Specialist
Lynne Boyle, Federal Relations Professional

  • The Health System Office of State and Federal Government Relations (“Government Relations”), headed by Sally Barber, works with Health System leadership to establish legislative and regulatory priorities. It coordinates with the academic division on state and federal issues, maintains relations with government officials, and serves as a resource to leadership, faculty, and staff for state and federal governmental matters.
  • Karen Rheuban, MD, is the SOM liaison to Government Relations.
  • Key legislation of the 2018 General Assembly session included:
    • Nurse Practitioner Pathway to Independent Practice (HB 793)
    • Medicaid expansion
    • Certificate of Public Need
    • Opioid/substance abuse
    • Termination of Medically/Ethically Inappropriate Care (HB 226/SB 222)
  • Health System priorities at the federal level include:
    • Health Resources and Services Administration’s (HRSA) 340B drug discount program
    • Medicare and Medicaid hospital and physician payments
    • Funding for the National Institutes of Health
    • Student loan programs
    • Regulatory relief for hospitals
    • Opioid abuse
  • State and Federal Dashboards of laws, regulations, and other activities being tracked are posted on the website,

Strategic Hiring Initiative: New Recruits and Exciting Collaborations

At the April 19 General Faculty Meeting, Dean David Wilkes provided updates on a range of topics, one of which was the Strategic Hiring Initiative (SHI). We are over two years into the 5-year plan where we are investing $60 million dollars to hire faculty who will help to strengthen our already outstanding research groups and to catalyze new initiatives and collaborations.

Through SHI and other strategic recruitment efforts, we’re hiring the best scientists and physician-scientists into thematic areas of organ transplant, metabolic disorders, precision medicine, and regenerative medicine. These themes build on the strengths of the previously identified areas of cancer, cardiovascular, and neurosciences, and intersect with areas of excellence in imaging, immunology, infectious diseases and genomics/epigenetics.  We have been particularly interested in hiring on the intersections of excellence, to seed future collaborations and interactions between our themes.

Our two most recent SHI hires are:

Imre Noth, MD

Imre Noth, MD

  • Pulmonary & Critical Care Division Chief
  • Has collaborations with Center for Public Health Genomics
  • Is an expert in clinical trial design, genomics, transcriptomics, pharmacogenomics
  • Comes to UVA from the University of Chicago



Ken Walsh, PhD

Ken Walsh, PhD

  • Professor of Cardiovascular Medicine
  • Studying the contribution of cumulative mutations in hematopoietic stem cells to a wide range of major chronic diseases including cancer, neurodegenerative diseases, autoimmune diseases, fibrotic diseases
  • Comes to UVA from Boston University


Recent SHI Collaboration in Action
The effect of SHI is not limited to the funding brought by the new hires. They are making an impact through collaborations across departments and across schools. A few highlights include:

  • Two SHI hires in transplant and adaptive cell therapy (Jose Oberholzer and Larry Lum) are part of a successful SIF application with Boris Kovatchev and Stephen Rich to treat and cure Type 1 diabetes.  Two additional SHI hires in Endocrinology (Andy Basu and Rita Basu) have joined this SIF effort, and have begun educational and research collaborations with the Cardiovascular Research Center and the Data Science Institute.
    • This larger diabetes group is mounting an effort to submit ten multi-Principle Investigator grants in response to a special NIH opportunity, which involves four SOM departments and two Engineering departments.
  • In Pediatrics (Sean Moore), is working with colleagues in Medicine (Bill Petri), the Global Infectious Diseases Institute and Alison Criss, and the Gates Foundation to develop a research facility and projects to study the influence of the microbiome on numerous diseases.
  • In Medicine and Biochemistry, Francine Garrett-Bakelman is part of a multiple PI consortium with Mazur Adli and colleagues in Biochemistry between the SOM, the College of Arts and Sciences, and Signature Sciences that is proposing to do research on the human epigenome in response to environmental toxins.
  • In Public Health Science, SHI hire Bob Klesges and colleagues in Psychiatry (Nassima Ait-Daoud Tiouririne, Lee Ritterband, Karen Ingersoll), Emergency Medicine (Chris Hostege), Medicine (L. Blackhall), Nursing (V. LeBaron) and Engineering (Laura Barnes and John Lach) are working together on a SIF project to reduce the burden of addiction, including a project to reduce binge drinking in college students.

The SHI committee, co-chaired by Dr. Coleen McNamara and me, review the nominations from chairs/directors. If you have questions regarding the Strategic Hiring Initiative, please contact Dr. McNamara (cam8c@virginia.edu) or me (mas3x@virginia.edu).

Margaret A. Shupnik, PhD
Gerald D. Aurbach Professor of Endocrinology
Professor of Medicine
Senior Associate Dean for Research

Second Cohort of JFDP Deliver Scholarly Projects


Top row, left to right: Andrew Schomer, David Hamilton, John McNeil, Dushant Uppal. Second row: Angie Nishio-Lucar, Elizabeth Gaughan, Andrea Garrod, Scott Sperling. Third row: Brent DeGeorge, Katherine Fedder, Thomas Hartka, Chantal Scott, Gina Andersen, Patrick Cottler. Front: Troy Buer and Susan Pollart

Last year, we wrote about the Junior Faculty Development Program (JFDP), which can be read here and here. This is a program that provides networking, social opportunities, and peer mentoring among colleagues who are at a similar stage in their career; promotes the development and advancement of junior faculty through seminars and mentored scholarly projects; and facilitates mentoring relationships between senior and junior faculty.

On April 11 and 25, the second cohort of 17 junior faculty members presented their scholarly projects, which explored a range of topics including an evaluation of machine learning for assignment of triage severity level in the emergency department, predicting cardiac instability following seizures, contraception and the medically complex woman, and improving access to kidney transplant for Hispanic minorities in the state of Virginia. The list of 2018 JFDP projects can be found here.

Congratulations to the 2017-2018 JFDP participants who graduated from the program!

Susan M. Pollart, MD, MS
Ruth E. Murdaugh Professor and Chair (interim) of Family Medicine
Senior Associate Dean for Faculty Affairs and Faculty Development

Where the Money Goes and How You Can Help

Dean David Wilkes

As you may have read, President Trump recently signed into law a $1.3 trillion omnibus spending package that funds the government for the remainder of federal fiscal year 2018. To the delight of many in the science community, this legislation provides a $3 billion, or greater than 8 percent, increase to the National Institutes of Health (NIH) for a total of $37.1 billion. The agreement was finalized after Congress extended temporary funding for the government five times and passed the Bipartisan Budget Act of 2018, which raises budgetary spending caps for defense and non-defense discretionary spending in both FYs 18 and 19.

Every NIH institute will receive roughly a five percent increase above FY 2017 funding — well above biomedical inflation. Importantly, this is the third year of meaningful growth for the NIH and a welcome investment, considering President Trump’s FY18 budget proposal to dramatically cut the NIH and support for facilities and administrative expenses.

Examples of increases in NIH research initiatives include:

  • $1.8 billion (+$414 million) for Alzheimer’s disease research;
  • $543 million (+27 million) for Clinical and Translational Science Awards;
  • $500 million for targeted research on opioid addiction, including $250 million for the National Institute of Neurological Disorders and Stroke (NINDS) and $250 million for the National Institute on Drug Abuse (NIDA);
  • $400 million (+$140 million) for the Brain Research through Application of Innovative Neurotechnologies (BRAIN) initiative;
  • $351 million (+17 million) for research on combating antibiotic-resistant bacteria;
  • $300 million for the Cancer Moonshot;
  • $290 million (+$60 million) for the All of Us research initiative (formerly called the Precision Medicine Initiative);
  • $100 million (+$40 million) for research to develop a universal flu vaccine;
  • $12.6 million for the Gabriella Miller “Kids First” pediatric cancer research initiative; and
  • $10 million (+$8 million) for regenerative medicine research.

The bill also supports a new multi-year Down syndrome research initiative that will expand NIH support for research on Trisomy 21 and related diseases and disorders.

This month, the House and Senate Appropriations Subcommittees that oversee NIH funding will begin their FY19 budget process, including holding hearings from Members of Congress and outside public witnesses on programmatic funding levels. I wish to share the letter I wrote to Rep. Scott Taylor, Virginia’s only member of the House Appropriations Committee, asking him to make the NIH a funding priority in FY19 because of the health and economic value that NIH funding brings to the Commonwealth. Our government relations team is also reaching out to Virginia’s congressional representatives to remind them that $377 million in NIH grants and contracts to UVA and other Virginia institutions brings 5,765 direct and indirect jobs to the Commonwealth and provides over $1 billion in economic activity.

Faculty can have a part to play in this, too. Your voice can be a powerful amplification to our current advocacy efforts in articulating why the NIH should receive sustainable and predictable funding. Should you be traveling to Washington, DC, this spring or summer for peer-review or professional association meetings and wish to meet with our Congressional delegation, I encourage you to contact Sally Barber or Lynne Boyle in the Office of Special Advisor and State and Federal Relations. If Sally or Lynne knows of your arrival in Washington, she can help coordinate efforts to share your message on research. Dr. Tim Rosean, a postdoctoral research associate studying immunology and lupus as part of Dr. Loren Erickson’s lab recently did, and was happy to lend his voice to the conversation.

If you do participate, drop me a note upon your return. I look forward to hearing about your visit.

David S. Wilkes, MD
Dean, UVA School of Medicine
James Carroll Flippin Professor of Medical Science

Highlights: March MAC Meeting

Opening Comments from the Dean
David S. Wilkes, MD

  • Dean Wilkes highlighted three individuals who received distinguished recognition:
    • B. Cameron Webb, MD, JD, Assistant Professor of Medicine and Public Health Sciences, was recognized by the Congressional Black Caucus and the National Minority Quality Forum as one of the “40 Under 40 Leaders in Minority Health.”
    • Pamela Sutton-Wallace, Medical Center CEO, was among the “Top 25 Minority Executives in Healthcare 2018” identified by Modern Healthcare.
    • Richard Baylis, MD/PhD student in Gary Owens’ lab, is among 600 students worldwide selected to attend the 68th Lindau Nobel Laureate Meeting. He will have the opportunity to meet and talk science with 43 Nobel Laureates.
  • IT Security Upgrade
    • The recent upgrade was made with the primary purpose of addressing urgent needs to ensure patient data is safe. This has brought about some unintended outcomes, such as variable access to programs and files resulting in work-arounds. The dean reminded people that Health System shared drives (e.g., “Y”) can be used for sharing or storing information, including PHI. Non-confidential information can be shared via UVA Box or Collab. Call the Help Desk at 434.924.5334 if you are having trouble accessing programs or files. We will have another update at the April MAC.

Funding Analysis/NIH Rankings
Margaret A. Shupnik, PhD

  • Dr. Shupnik showed a chart of funding over a 10-year period and noted that total funding is up and we are diversifying our portfolio. There has been a big increase in successful non-modular grants.
  • The NIH ranking contains all awards – new, renewed, non-competitive continuations, and supplements of all types of awards. It includes all subcontracts if the PI is at UVA and does not include NIH subcontracts received from other institutions.
  • There is considerable volatility of dollars awarded among the rankings of 35-45 and one grant has the potential to bring about an increase or a decrease in the rankings.
  • Dr. Shupnik’s analysis shows that we have many fewer P and U grants than other institutions and this appears to be the primary factor in our ranking not being higher. These awards enable scientists to do the kind of work that one person cannot do alone, and they bring more than funds – they also bring impact and status within the scientific community and provide infrastructure and administrative support.
  • Resources are available – ResearchNet, the Conafay Group – at the institutional level, in addition to department resources such as pre-submission grant review. ResearchNet can provide some shared SOM/VPR support for complicated team/center proposal submissions.
  • NIH rankings information is at http://www.brimr.org/NIH_Awards/NIH_Awards.htm.

On the Path to Academic Success
Susan M. Pollart, MD

  • Annual reviews, which are required for every faculty member, are especially important for faculty at the end of their first three years. For tenure eligible faculty members, it is important to realistically assess potential for the first promotion. For tenure ineligible faculty, the appointment after the third year of employment must be for three years. Regardless of tenure eligibility, faculty members not meeting expectations at the end of the third year of employment can be given a one year notice of non-renewal.
  • Promotion and Tenure
    • New guidelines provide updated/clarified guidelines regarding criteria for excellence in team science.
    • Dean Wilkes is sending the SOM P&T Committee’s specific recommendations to individual faculty members (promoted on July 1, 2017) who are eligible for further advancement (i.e. tenured associate professors, tenure eligible associate professors, and tenure ineligible associate professors). These recommendations identify areas to recommended focus to help ensure success in their next advancement.

Health System Financial Overview
Douglas Lischke, Chief Accounting Officer

  • Mr. Lischke provided an update of the consolidated Health System financials.

Health System Board Update
A. Bobby Chhabra, MD

Dr. Chhabra shared highlights from the February 28, 2017, HSB meeting. The HS goals dashboard for FY18 showed strong performance with eight out of twelve indicators green.

The next meeting will be Tuesday, April 10, 2018, in the BIMS Classroom.

Act Now: Addressing Opioid Addiction


This semester the School of Medicine and colleagues across Grounds are gathering for a series of discussion groups with faculty who are interested in doing research related to substance misuse and addiction, particularly involving opioids. This is a great moment of opportunity for our School as in December 2017 the Board of Visitors approved Strategic Investment Funds (SIF) for “Reducing the Burden of Addictions in Virginia.” Our goal is to use this initiative as a stepping stone for more collaborative activities across Grounds.

On January 25, 25 faculty from across the University, representing 17 different departments, institutes, and units, gathered for the first meeting.* The meeting included presentations on structure and funding opportunities; preventing opioid misuse; limiting the supply of opioids and advancing pain management; treating opioid-addicted individuals; and the legal, policy, and economic implications of the epidemic.

Discussion included:

  • whether this crisis was, at its foundation, about pain and its treatment;
  • while there is a need for basic neurological research regarding pain, the crisis is about more than physical pain;
  • the larger social and historic context of substance abuse; and
  • questions regarding how to prevent or reduce the harms associated with substance misuse and addiction, particularly to opioids.

After the 90-minute session, the group’s recommendation was to:

  • Develop strategic teams focused on key domains of transdisciplinary research; e.g., preventing addiction, treating addiction (including practice changes), neurobiology of pain, and drug policy.
  • Convene more meetings with stakeholders in these and other domains of transdisciplinary research to generate cohesive research white papers for dissemination to partners and sponsors.
  • Distribute white papers at the Virginia Higher Education Conversation on Opioid Use and Addiction (May 1) and identify prospective partners from across the state and region.
  • Develop and implement additional structures to support transdisciplinary science in these domains, including but not limited to, pre-proposal planning for strategic cross-Grounds applications.

Transdisciplinary collaborations are necessary to prevent or mitigate the effects of opioid misuse and addiction in the Commonwealth of Virginia. As such, these discussions are ongoing and open to all. It is my hope that you will join the conversation. If you are interested, please contact David Driscoll, PhD, Director of Research Development in the School of Medicine, and a member of the VPR ResearchNet group that develops and participates in large transdisciplinary research projects within their schools and across Grounds.

*Participants represented the Dean’s Office; ResearchNET; Psychiatry and Neurobehavioral Sciences; Systems and Information Engineering; General Medicine, Geriatrics and Palliative Care; the Institute of Law, Psychiatric and Public Policy; Government Relations; the Center for Global Health; Center for Public Health Policy; Anesthesiology; the Brain Institute; the Division of Infectious Diseases and International Health; Emergency Medicine;  Anthropology; Public Policy and Economics; and Electrical and Computer Engineering.

Margaret A. Shupnik, PhD
Gerald D. Aurbach Professor of Endocrinology
Professor of Medicine
Senior Associate Dean for Research

Come Celebrate Medical Education!


Many medical schools around the country celebrate education by holding a Medical Education Day. Here at UVA, a single day cannot do it justice. As such, every year we have a full week dedicated to medical education. This year, Medical Education Week will run from March 12-16.

We have many educators at the School of Medicine who work tirelessly all year long to accomplish the goals of our educational mission. Medical Education Week is a great opportunity to put a spotlight on the work our faculty, residents, and students do to innovate in medical education.

The week is co-sponsored with the Brodie Medical Education Fund, which annually supports an internationally known speaker in medical education. This year we welcome Dr. Elizabeth Gaufberg from Harvard Medical School to discuss “assumptions we bring to learning and practice.”

Here’s a quick rundown of what to expect this year:

March 12 – 16: Poster Session
Posters will be on display outside the Claude Moore Health Sciences Library.

March 13: Medical Education Research Presentations
Noon – 1 p.m. | G1/G2 Pinn Hall Conference Center
Lunch will be available; register here.

  • Noon – 12:30 p.m.: Processed EEG indices correlate with NASA-TLX Measurements of Cognitive Load by Drs. John Kwock, Ali Kazemi, Noah Schenkman, and Keith Littlewood (presenter)
  • 12:30-1  p.m.: Does wisdom protect against depersonalization among medical students? by Drs. John Schorling, Peggy Plews-Ogan, Rachel Kon, Tabor Flickinger (presenters), and Justine Owens

March 14 | The Brodie Medical Education Lecture/Medical Grand Rounds/Medical Center Hour
Noon – 1 p.m. | Pinn Hall Conference Center Auditorium
What We See, What We Feel, What We Say — Exploring Assumptions We Bring to Learning and Practice | Presented by Elizabeth H. Gaufberg, MD, MPH, Departments of Medicine and Psychiatry, Harvard Medical School; Cambridge Health Alliance, Cambridge MA; and the Arnold P. Gold Foundation

March 14 | Medical Education Week Reception
5 p.m. – 7 p.m. | Claude Moore Health Sciences Library (2nd floor)
Poster presentations (presenters available from 5-6 p.m.); remarks by Dean David Wilkes and Dr. Gaufberg at 6 p.m.

March 15 | Medical Education Research Presentations
Noon – 1 p.m. | G1/G2 Pinn Hall Conference Center
Lunch will be available; register here.

  • Noon – 12:30 p.m.: Learning curves for robotic surgery fundamentals among novices, by Drs. Yinin Hu, Helen Kim (presenter), Philip Smith, Peter Hallowell, Leigh Cantrell, Noah Schenkman, Sara Rasmussen
  • 12:30 – 1 p.m.: Vessel Ligation Fundamentals: A Comparison of Technical Evaluations by Crowdsourced Nonclinical Personnel and Surgical Faculty, by Drs. Yinin Hu (presenter), Helen Kim, Bo Jiang, Anneke Schroen, Philip Smith, Sara Rasmussen

Thank you to the Brodie committee, the Academy of Distinguished Educators, and all of our faculty, residents, and students who contribute to making this such a successful event.

R.J. Canterbury, MD
Senior Associate Dean for Education
Wilford W. Spradlin Professor